Characteristics of the development cohort for individual scores
| . | . | HCT-CI2 . | Comorb-age8 . | Integrated score11 . | Aug-HCI26 . | PAM14 . | rPAM16 . | EASIX22 . | SCI19 . | EBMT-PTCy12 . |
|---|---|---|---|---|---|---|---|---|---|---|
| No. of pts | 708 | 3033 | 812 | 3917 | 1401 | 1549 | 311 | 573 | 1,861 | |
| Median age | 45 (1-73) | n/a | 58 (20-76) | n/a | n/a | 51 (15-79) | 53 (17-70) | 56 (46-64)a | 51 (18-79) | |
| Years | 1997-2003 | 2000-2006 | 2000-2011 | n/a | 1990-2002 | 2003-2009 | 2001-2013 | 2008-2018 | 2010-2018 | |
| Donor type | Related | 612 (58%) | 1677 (55%) | 432 (53%) | 1962 (50%) | 663 (47%) | 584 (38%) | 109 (35%) | 195 (34%) | 254 (14%) |
| Unrel. | 443 (42%) | 1356 (45%) | 380 (47%) | 1942 (50%) | 738 (53%) | 886 (57%) | 189 (61%) | 378 (66%) | 1607 (86%) 56% haplo | |
| Stem cell source | Marrow | 306 (29%) | 660 (22%) | n/a | n/a | 1059 (76%) | n/a | 202 (6%) | 0 (0%) | 507 (27%) |
| PB | 749 (71%) | 2373 (78%) | n/a | n/a | 329 (23%) | n/a | 291 (94%) | 573 (100%) | 1354 (73%) | |
| Cord | 0 (0%) | 0 (0%) | n/a | n/a | 0 (0%) | n/a | 20a (6%) | 0 (0%) | 0 (0%) | |
| Regimen intensity | MAC | 760 (72%) | 1,889 (62%) | 0 (0%) | 2083 (53%) | 1314 (94%) | 940 (61%) | 72 (23%) | 573 (100%) | 561 (30%) |
| RIC | 295 (28%) | 295 (28%) | 812 (100%) | 1810 (46%) | 87 (6%) | 609 (39%) | 239 (77%) | 0 (0%) | 1300 (7%) | |
| T-cell depletion | None specified | 708 (100%) | 2790 (92%) | 472 (58%) | n/a | n/a | n/a | 122 (39%) | 0 (0%) | 0 (0%) |
| ATG | n/a | 243 (8%) | 340 (42%) | n/a | n/a | n/a | 189 (61%) | 0 (0%) | 0 (0%) | |
| PTCy | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0 (0%) | 1861 (100%) | |
| CD34 selection | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 573 (100%) | 0 (0%) |
| . | . | HCT-CI2 . | Comorb-age8 . | Integrated score11 . | Aug-HCI26 . | PAM14 . | rPAM16 . | EASIX22 . | SCI19 . | EBMT-PTCy12 . |
|---|---|---|---|---|---|---|---|---|---|---|
| No. of pts | 708 | 3033 | 812 | 3917 | 1401 | 1549 | 311 | 573 | 1,861 | |
| Median age | 45 (1-73) | n/a | 58 (20-76) | n/a | n/a | 51 (15-79) | 53 (17-70) | 56 (46-64)a | 51 (18-79) | |
| Years | 1997-2003 | 2000-2006 | 2000-2011 | n/a | 1990-2002 | 2003-2009 | 2001-2013 | 2008-2018 | 2010-2018 | |
| Donor type | Related | 612 (58%) | 1677 (55%) | 432 (53%) | 1962 (50%) | 663 (47%) | 584 (38%) | 109 (35%) | 195 (34%) | 254 (14%) |
| Unrel. | 443 (42%) | 1356 (45%) | 380 (47%) | 1942 (50%) | 738 (53%) | 886 (57%) | 189 (61%) | 378 (66%) | 1607 (86%) 56% haplo | |
| Stem cell source | Marrow | 306 (29%) | 660 (22%) | n/a | n/a | 1059 (76%) | n/a | 202 (6%) | 0 (0%) | 507 (27%) |
| PB | 749 (71%) | 2373 (78%) | n/a | n/a | 329 (23%) | n/a | 291 (94%) | 573 (100%) | 1354 (73%) | |
| Cord | 0 (0%) | 0 (0%) | n/a | n/a | 0 (0%) | n/a | 20a (6%) | 0 (0%) | 0 (0%) | |
| Regimen intensity | MAC | 760 (72%) | 1,889 (62%) | 0 (0%) | 2083 (53%) | 1314 (94%) | 940 (61%) | 72 (23%) | 573 (100%) | 561 (30%) |
| RIC | 295 (28%) | 295 (28%) | 812 (100%) | 1810 (46%) | 87 (6%) | 609 (39%) | 239 (77%) | 0 (0%) | 1300 (7%) | |
| T-cell depletion | None specified | 708 (100%) | 2790 (92%) | 472 (58%) | n/a | n/a | n/a | 122 (39%) | 0 (0%) | 0 (0%) |
| ATG | n/a | 243 (8%) | 340 (42%) | n/a | n/a | n/a | 189 (61%) | 0 (0%) | 0 (0%) | |
| PTCy | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0 (0%) | 1861 (100%) | |
| CD34 selection | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 573 (100%) | 0 (0%) |
Provided in the original article as median and interquartile range.
described in the original article as “bone marrow or unrelated cord blood.”
ATG, antithymocyte globulin; Aug-HCI, augmented HCT-CI; Comorb-Age, comorbidity-age score; unrel, unrelated; PB, peripheral blood; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.